Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00415714
Other study ID # H300
Secondary ID
Status Recruiting
Phase N/A
First received December 21, 2006
Last updated January 26, 2007
Start date September 2006
Est. completion date October 2007

Study information

Verified date December 2006
Source Helicor
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The objective of this study is to determine the efficacy of a portable biofeedback device on improving sleep latency and other sleep variables such as nocturnal awake time and daytime functioning in persons with primary insomnia.


Description:

There is evidence that when compared to normal controls, persons with insomnia exhibit increased cognitive and physiological arousal and higher overall metabolic rate during sleep, particularly at sleep onset. There is evidence that reducing this arousal may impact sleep latency and nocturnal awake time. Although relaxation treatments have been integrated into behavioral therapies, there are numerous barriers to their implementation in real world settings. The present study is designed to examine the effect of a portable biofeedback device designed to induce physiological relaxation as compared to an inactive sham control device condition in reducing sleep onset latency in persons with primary insomnia over a 4 week period at three separate research sites.


Recruitment information / eligibility

Status Recruiting
Enrollment 132
Est. completion date October 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

1. Between the ages of 18-55

2. Met DSM-IV-TR criteria for Primary Insomnia as measured by the:

- Structured Interview for Sleep Disorders.

- Insomnia Severity Index (>14).

3. Demonstrate Sleep Onset Latency of >=45 minutes on >= 3 nights per week greater than or equal to 6 days over the 2 week period.

4. A mean SOL >= 30 minutes over the 2 week period between Screening and Baseline visits.

5. Residential stability (1 year) and means to travel to appointments.

6. Willing to provide the name and contact information of a secondary contact person.

7. Off insomnia medications for at least one week prior to randomization and no more than 2 days of use during the first week of baseline.

8. Ability to read in English.

9. Provision of informed consent.

10. Willing to comply with daily protocol.

11. Ability to obtain a reading on the device.

Exclusion Criteria:

1. Been in more than 2 studies in the past 2 years

2. Pregnant

3. Terminal, progressive, and or unstable medical illness.

4. Self-reported sleep disruptive medical disorder i. Chronic Pain, Fibromyalgia, Pheochromocytoma, Hyperthyroidism, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes.

5. Current Axis I psychiatric disorder.(DSM-IV) i. Major Depressive Disorder, Depression, Generalized Anxiety Disorder, Attention Deficit Disorder, Post Traumatic Stress Disorder, Bipolar Disorder, Substance/Alcohol Use Disorders, Attention Deficit Hyperactivity Disorder, Schizophrenia/Psychotic Disorders, Delirium, Dementia, and/or Amnesic disorders, Panic Disorder w/ nocturnal panic attacks.

6. Chronic alcohol use not diagnosed in criterion 6. i. Subjects unwilling to limit their alcohol intake to 2 standard drinks per day will be excluded.

7. Raynaud’s Disease

8. Regularly taking anti-anxiety medications, beta blockers or other heart medications that regulate heartbeat, bronchodilators, respiratory stimulants, simulating antidepressants, sedating antidepressants, thyroid supplements, anti-psychotics, and/or steroids.

9. Regularly taking antidepressants (Prozac, Zoloft, Paxil) and NOT on a fixed dosage for at least 1 month prior to entering the study.

10. Regularly taking medication (prescribed or over the counter) for sleep difficulties (>3x week). Sleep medications include any substance for sleep not limited to but including FDA approved sleep medications, analgesics, antihistamines, decongestants, melatonin, L-trypotophan, and velarian.

11. Unwilling to abstain from PRN sleep aides (prescribed or over the counter).

12. Restless Leg Syndrome as assessed by structured interview.

13. Symptoms of Sleep Apnea (BMI>32 and Epworth Sleepiness Scale >10)

14. Own a negative air ionizer or have used one in the past to treat insomnia.

15. If subject recognizes device during the ability to obtain a pulse rate wave reading on the device.

16. More than 5 cups (8oz) of caffeinated drinks per day and/or unwilling to limit caffeine in-take to a maximum of 3 cups a day and not after 5pm during the intervention.

17. Regular night-time shift work and rotating night-time shift work.

18. Idiopathic Insomnia.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Portable Biofeedback


Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Helicor

Country where clinical trial is conducted

United States, 

References & Publications (1)

Morin CM, Hauri PJ, Espie CA, Spielman AJ, Buysse DJ, Bootzin RR. Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep. 1999 Dec 15;22(8):1134-56. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Sleep latency at 4 week follow-up
Secondary wake time after sleep onset (WASO) at 4 week follow-up
Secondary total awake time (SOL + WASO) at 4 week follow-up
Secondary Shifting from moderate/severe insomnia to mild/no insomnia (Insomnia Severity Index)at 4 week follow-up
Secondary Daytime functioning at 4 week follow-up
See also
  Status Clinical Trial Phase
Terminated NCT03461666 - Comparison of Efficacy of Behavioral Approaches for Treatment of Insomnia N/A
Recruiting NCT02243501 - Better Nights, Better Days for Typically Developing Children N/A
Completed NCT01636791 - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care Phase 3
Completed NCT00770510 - A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126) Phase 2/Phase 3
Completed NCT00520832 - A Pilot Study Of The Effects Of Microcurrent On Three Sleep Surveys Phase 2
Terminated NCT00420810 - Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED) Phase 3
Completed NCT00178048 - Paroxetine in the Treatment of Chronic Primary Insomnia Phase 4
Completed NCT00816673 - Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs Phase 2
Completed NCT01957111 - Metabolomics of Insomnia-Related Hyperarousal N/A
Completed NCT01960452 - A High Density EEG Comparison of Sleep Patterns in Insomnia N/A
Completed NCT01181232 - A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients Phase 4
Completed NCT00784875 - An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia Phase 2
Completed NCT00551148 - A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia Phase 2
Completed NCT00397189 - Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients Phase 3
Completed NCT00352144 - 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia Phase 3
Completed NCT02290405 - Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers
Completed NCT03314441 - Effects of Regular Practice of Yoga on Subjective and Objective Sleep Quality in Primary Insomnia N/A
Completed NCT00792298 - Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006) Phase 2
Completed NCT01021852 - Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011) Phase 2
Completed NCT01719315 - Neurophysiologic Correlates of Hypersomnia

External Links